The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

239

Participants

Timeline

Start Date

November 9, 2017

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
DRUG

OPC-64005

OPC-64005 film coated tablets

DRUG

Atomoxetine

Atomoxetine gelatin capsules

DRUG

Placebo

OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules

Trial Locations (26)

10128

Eastside Comprehensive Medical Center, LLC., New York

The Medical Research Network, LLC, New York

30030

iResearch Atlanta, Decatur

30060

Northwest Behavioral Research Center, Marietta

32256

Clinical Neuroscience Solutions, Inc, Jacksonville

32801

Clinical Neuroscience Solutions, Inc., Orlando

32806

Clinical Neuroscience Solutions Inc., Orlando

33161

Behavioral Clinical Research, Inc., North Miami

33319

Innovative Clinical Research, Inc., Lauderhill

34201

Meridien Research, Bradenton

66223

Psychiatric Associates, Overland Park

68526

Premier Psychiatric Research Institute, LLC, Lincoln

73103

IPS Research Company, Oklahoma City

73118

Paradigm Research Professionals, Oklahoma City

78229

Clinical Trials of Texas, Inc., San Antonio

80910

MCB Clinical Research Centers, LLC, Colorado Springs

84058

Aspen Clinical Research, Orem

89128

Center for Psychiatry and Behavioral Medicine Inc., Las Vegas

90210

Southern California Research, LLC, Beverly Hills

92078

Artemis Institute for Clinical Research, San Marcos

92103

Artemis Institute for Clinical Research, San Diego

92845

Collaborative Neuroscience Network, LLC, Garden Grove

97214

Oregon Center for Clinical Investigators, Inc., Portland

97301

Oregon Center for Clinical Investigators, Inc., Salem

02865

BTC of Lincoln, Lincoln

05091

Neuropsychiatric Associates, Woodstock

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT03324581 - The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder | Biotech Hunter | Biotech Hunter